Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TargetTau-1 in early Alzheimer's disease
jRCT2051240052Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial of PRX005 in Alzheimer's disease (AD) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Mean change from baseline in Clinical Dementia Rating Scale Sum of Boxes score. Started Jul 2024; status: active, not recruiting.
02
Drugs
PRX005
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2051240052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240052.